US3875300A - Composition for sustained release of a medicament and method of using same - Google Patents

Composition for sustained release of a medicament and method of using same Download PDF

Info

Publication number
US3875300A
US3875300A US316175A US31617572A US3875300A US 3875300 A US3875300 A US 3875300A US 316175 A US316175 A US 316175A US 31617572 A US31617572 A US 31617572A US 3875300 A US3875300 A US 3875300A
Authority
US
United States
Prior art keywords
composition
spermicide
medicament
ethanol
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US316175A
Other languages
English (en)
Inventor
Roger Homm
Gilbert Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Priority to US316175A priority Critical patent/US3875300A/en
Priority to FR7344027A priority patent/FR2210415B1/fr
Priority to GB5704473A priority patent/GB1446626A/en
Priority to BE138771A priority patent/BE808519A/xx
Priority to ZA00739502A priority patent/ZA739502B/xx
Priority to IT54360/73A priority patent/IT1047937B/it
Priority to AU63720/73A priority patent/AU6372073A/en
Priority to JP48139715A priority patent/JPS49133519A/ja
Priority to BR9861/73A priority patent/BR7309861D0/pt
Priority to IL43839A priority patent/IL43839A0/xx
Priority to NL7317324A priority patent/NL7317324A/xx
Priority to DE2362991A priority patent/DE2362991A1/de
Priority to AT1060573A priority patent/AT332532B/de
Application granted granted Critical
Publication of US3875300A publication Critical patent/US3875300A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Definitions

  • ABSTRACT A solid, intimately admixed compostion comprising a thermoplastic, physiologically-inert polymer soluble in body fluids, andan effective amount of a suitable medicament.
  • the composition is suitable for introduction into a body cavity, therein to be slowly dissolved by body fluids and release thereby incremental amounts of medicament.
  • Various areas of use include intravaginal applications for spermicidal effect, subcutaneous implantation, and the, like.
  • the present invention relates to an improved medicament dispensing system of special use in contraception. More particularly it relates to a composition of matter useful for delivering controlled amounts of a medicament within a body cavity at a pre-determined rate.
  • Delivery of medicaments to a site within a body cavity is usually accomplished either systemically by oral administration or locally by direct introduction into the cavity.
  • the systemic method has the advantage of being convenient, but because it is systemic suffers from side effect" problems.
  • Direct introduction has the advantage of requiring lower doses and is faster acting, but is also usually very inconvenient and quite often unpredictable in efficacy.
  • the concentration of medicament in the body cavity is not maintained at a constant level, but is rather at a maximum just after application and declines thereafter.
  • it is necessary when using the direct introduction method to give either a moderate excess at short intervals or a large excess at longer intervals. Neither of these alternatives is satisfactorily convenient or economical.
  • contraception One of the areas of major interest as regards direct introduction of medicaments into body cavities is contraception.
  • Several contraceptive methods are currently employed. For example, there are those which prevent ovulation, those which prevent implantation, and those which prevent sperm from coming in contact with a released ovum.
  • the first method is typified by oral administration of various drugs, usually steroids, and has the disadvantage of being systemic rather than topical. It is advantageous, however, in that administration immediately prior to coitus is not necessary.
  • the second method is typified by insertion into the uterus and maintenance therein of a foreign object called an intrauterine device.
  • This method has the advantage of the first method and is also topical, but is disadvantageous because of the undesirably high possibility of perforating the uterus.
  • the devices are usually painful during the insertion process and usually for long periods thereafter during residency.
  • a third method usually involves placing some physical or chemical barrier between the sperm and the ovum and is typified by a condom, a spermicidal foam or jelly, and the like, or a combination of two or more of these.
  • This third type has the disadvantage of requiring application just prior to coitus, but has the advantages of being topical in application and having no extravaginal effects.
  • This method would be very desirable indeed if application of the material were required not immediately before coitus but rather at some prior time much in advance of coitus.
  • the present invention provides a system and method especially suited for contraceptive use of the third type, but capable of broader applications which does not have the disadvantages traditionally associated with it. That is, the invention provides a solid drug delivery system of the type which is inserted into the vagina up to 24 hours prior to coitus and slowly releases a spermicide. The system does not require removal or storage after use since it is soluble in body fluids and is diffused by the system.
  • the present invention therefore, in its broader aspects provides a solid drug delivery system comprising in intimate admixture a body fluid-soluble, thermoplastic, physiologically-inert polymer and an effective amount ofa suitable medicament.
  • medicament includes but is not limited to spermicides, ovacides, antimicrobials, anti-inflammatories, steroidal and non-steroidal anti-fertility agents, prostaglandins, and the like, and includes any compound, drug or medicine having a desired physiological effect.
  • the polymer may be any of those which are soluble in body fluids such as, for example, a cellulose, a starch, an alginate, a polyvinyl alcohol, a polyvinyl pyrrolidone, a polyacrylamide, an ethyleneoxide polymer, or the like.
  • the solubility characteristics of the polymer are chosen so that the entire mass is totally dissolved in the body cavity fluids within a period of about 24 hours so as to give a sustained, prolonged release of medicament.
  • the preferred polymer is a hydroxypropyl cellulose or hydroxypropylmethyl cellulose having a molecular weight of from 60,000 to 1,000,000.
  • cellulose ethers having a high degree of ideal propyl substitution at the hydroxyl groups. From to I00 percent propyl substitution is suitable.
  • the product of the invention may be provided in the form of fibers, molded articles or extruded shapes, in which form they may then be placed in the body cavity where they will dissolve and release the medicament at a desirable rate.
  • composition of the present invention will contain various amounts of polymer and medicament relative to one another depending upon many factors including the final use to which the composition will be put, the nature of the drug employed, the actual solubility characteristics of the polymer, and the like. In general, however, a composition containing up to about 30 weight percent of the medicament with the balance being essentially polymer will be suitable. Preferably, however, the amount of medicament ranges from 5 to 25 percent by weight based on the weight of the entire composition. Such a formulation is especially suitable for contraceptive use when the composition comprises a spermicide as the medicament and hydroxypropyl cellulose as the polymer.
  • compositions of the present invention are prepared by intimately blending the desired polymer in any convenient form such as pellet or powder form with the appropriate amount of medicament. This intimate mixture is then spun, cast, molded, or extruded into fibers or suitable shapes, either with or without the addition of solvents or additional plasticizers.
  • hydroxypropyl cellulose As illustrative, a typical preparation is as follows: Hydroxypropyl cellulose powder is intimately mixed with a suitable amount of a medicament, preferably a spermicide. The resulting mixture is melt spun using standard spinning techniques into a strand and the strand chopped into pellets. These pellets are then charged into a standard melt spinning apparatus, are spun into fine fibers and the fibers chopped into lengths convenient for subsequently forming cotton' balls from the fibers. Dry carding techniques are then employed to form cotton balls or wads. There results from this operation the preferred form of the composition of the invention when an intravaginal contraceptive system is sought.
  • the pellets may, on the other hand, be used in the molding or extrusion of a suitable shape, e.g., a circular film, a diaphragm, or the like.
  • the techniques of fiber formation may vary depending on the particular polymer being used, but these techniques are all within the skill of the art and basically form no part of the present invention.
  • a suitable coagulating agent e.g.,'Na SO,, (NH SO MgSO or the like
  • Standard wet spinning techniques are also employed when using hydroxypropylmethyl cellulose.
  • the preferred composition of the present invention is a mixture of hydroxypropyl cellulose with a spermicide, preferably in the form of a fibrous mass.
  • the spermicide may be any compound known to be spermicidal and compatible with the polymeric system used. Typically acceptable are non-ionic surfactants such as ethoxylated phenoxyethanols.
  • Such materials are well known in the art and are represented by pdiisobutylphenoxypolyethoxy ethanol, known as Triton X-l00, available from Rohm & Haas, Philadelphia, Pa., nonylphenoxypoly(ethoxy),, ethanol (where n is an integer up to 21 and preferably 9), known as Tergitol TP-9 available from Union Carbide, New York, N.Y., also known as Nonoxynol, available from General Aniline & Film Corp., New York, NY.
  • Other spermicides include ricinoleic acid and mercurial salts such as phenyl mercuric acetate.
  • the preferred spermicides are the nonylphenoxypoly(ethoxy),, ethanols with that compound wherein n is 9 being most preferred.
  • the fibrous mass suitably comprises polymerspermicide fibers having a strand diameter of up to 50 denier (about 5.5 mils.) and preferably from 0.0004 to 0.0015 inches, and a strand length of from 0.25 to 2 inches and preferably 0.5 to 1.25 inches.
  • the mass has a bulk density of 0.1 to 0.3 and preferably 0.1 l to 0.15 gms. per cc in the relaxed state.
  • Such dimensions give a product having the appearance of cotton wadding but having sufficient resiliency and elasticity for filling the cross-section of the vaginal canal and providing occlusion of the deep inner recesses and folds, which might otherwise not receive spermicide were a foam, jelly or cream used.
  • an effective fibrous mass weighs between 0.75 and 1.50 gms. and preferably 1.00 to 1.25 gms. It may be inserted into the vaginal canal using any of the well-known insertion techniques up to 16-24 hours before coitus. A mass of the weight and dimensions described will slowly dissolve over this period in the natural body fluids and will supply an effective dose of spermicide. It thus provides both a physical and chemical barrier to the union of sperm and ovum in a safe, reliable, topical and aesthetic fashion.
  • Observations of residence times of various embodiments of the present invention in several types of experimental animals indicate that it has the desired residence time (about 16 hours) in any warm-blooded animal if used at an appropriate dose.
  • fibrous masses weighing 1.00 to 1.25 gms. will have 0.10 to 0.125 gms. of spermicide associated therewith, and this will ordinarily be suitable for virtually complete spermicidal activity over a 16- hour period.
  • Other compositions of the invention, whether fibrous or molded or extruded shapes behave similarly and are easily adaptable to insertion into any body cavity therein to release drug.
  • EXAMPLE 1 lnto an oscillating drum mixer are charged 15,2000 gms. of powdered food grade hydroxypropyl cellulose (available under the tradename Klucel G (available from Hercules, lnc., Wilmington, Del., having a molecular weight of 275,000 and an idealized molar substitution of 3.0 and 1,800 gms. of diisobutylphenoxypolyethoxy ethanol, available under the name of Triton X- 100, from Rohm & Haas, Philadelphia, Pa.
  • the blend is intimately mixed and the resulting intimate mixture is charged into a 2-inch Davis-type single screw extruder equipped with a die containing six /s-inch circular orifices.
  • the Extruder has three zones of melting electrically maintained at 325F, 315F, and 330F, respectively.
  • the strands are cooled as they travel down a 30-foot teflon-coated trough, at the end of which is a means for chopping the strands into /2 inch lengths.
  • the resulting pellets are graded for size, the scraps being returned to the extruder for reuse.
  • the pellets are then re-extruded as above on a l-inch Davis-type extruder equipped with a die containing a 0.018 inch circular orifice and a means for attenuating the strand as it emerges. This monofilament is collected and is chopped into lengths of between about /2 inch and about 2 inches. These lengths are then treated by standard dry-carding techniques to yield fibrous masses of the cotton wad type.
  • Example II The procedure of Example I is repeated except that 15 percent by weight of the spermicide is substituted for the 10 percent used therein.
  • Example 1 The procedure of Example 1 is repeated except that 25 percent by weight of the spermicide is substituted for the 10 percent used therein.
  • Example V The procedure of Example IV is repeated except that 15 percent by weight of spermicide is substituted for the 10 percent used therein.
  • EXAMPLE VI A wad of fibers as produced in Example 11 and weighing 0.300 gms. is inserted into the vagina of a female rhesus monkey and is observed periodically. Dissolution of the polymer begins immediately and continues until the wad disappears, a period of from about 17 to about 24 hours.
  • EXAMPLE Vll Into a tank are charged parts by weight of a watersoluble copolymer of polyvinyl alcohol and allyl alcohol prepared in accordance with known techniques, (See Example I of US. Pat. No. 2,909,502), 5 parts by weight of the spermicide Triton X-l (diisobutylphenoxypolyethoxy ethanol) and sufficient water to make a l percent by weight spinning solution of the spermicide mixture. After thorough mixing, filtration, and de-aeration of the spinning solution, fiber is spun from the solution by the wet method, the coagulating solution for which is a 50C aqueous solution containing about 420g/liter of Na SO and having a pH of about 3.9. The monofilament is collected and chopped into staples (-l inch lengths) suitable for formation into cotton balls by standard dry carding techniques.
  • Triton X-l diisobutylphenoxypolyethoxy ethanol
  • Example VIII The procedure of Example VII is repeated except that 15 percent by weight of spermicide is substituted for the 5 percent used therein.
  • Example VII The procedure of Example VII is repeated except that 25 percent by weight of spermicide is substituted for the 5 percent used therein.
  • Example VII The procedure of Example VII is repeated except that 5 percent by weight of Tergitol TP-9 is substituted for the spermicide used therein.
  • Example XI The procedure of Example X is repeated except that 10 percent by weight of spermicide is substituted for the 5 percent used therein.
  • Example XII The procedure of Example X is repeated except that percent by weight of spermicide is substituted for the 5 percent used therein.
  • Example XIII The procedure of Example VII is repeated except that an equal weight ofeach of ricinoleic acid, and phenyl mercuric acetate is substituted for the 5 percent by weight of Triton X-l00 used therein.
  • EXAMPLE XIV Several fibers as produced in Example II are dissolved in saline solution and are added to rabbit semen samples in vitro. Immobilization of the sperm is observed to occur. Similar results are obtained when the fibers of Examples l-XIV are utilized in this manner.
  • a composition of matter comprising an intimate admixture of a thermoplastic, physiologically-inert hydroxypropyl cellulose or hydroxypropylmethyl cellulose polymer soluble in vaginal fluids shaped as an intra-vaginal medicament applicator and up to 30 weight percent of a vaginal medicament, said intimate mixture having been melt spun by being melted, spun, cast, molded or extruded in the molten state into a fibrous mass of fine fibers, strands, pellets, balls or wads, the entire mass totally dissolving in said vaginal fluid within about 24 hours.
  • composition of claim 1 wherein the polymer is hydroxypropyl cellulose.
  • composition of claim 2 in which the medicament is a spermicide, ovacide, antimicrobial, prostaglandin, steroidal or non-steroidal antifertility agent.
  • composition of claim 3 wherein the medicament is a spermicide.
  • composition of claim 4 wherein the spermicide is present in an amount ranging from 5 to 25 percent by weight based on the weight of the entire composition.
  • composition of claim wherein the polymer is a hydroxypropyl cellulose.
  • composition of claim 6 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol wherein n is 9.
  • composition of claim 6 wherein the spermicide is p-diisobutylphenoxypolyethoxy ethanol.
  • composition of claim 5 wherein the polymer is a hydroxypropylmethyl cellulose.
  • composition of claim 9 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
  • composition ofclaim 6 wherein the composition is in the form of a fibrous mass having a fiber diameter of from 0.0004 to 0.0015 inches, and a bulk density of from 0.1 l to 0.15 gms. per cubic cm.
  • composition of claim 11 wherein the spermicide is nonylphenoxypoly(ethoxy),, ethanol or pdiisobutylphenoxypolyethoxy ethanol wherein n is a number up to 21.
  • the method for delivering a vaginal medicament to a site within the vagina from a solid medicament delivery system which comprises introducing within the vagina an effective amount of the composition of claim 1.
  • composition employed is from 5 to 25 percent by weight of a spermicide admixed in a hydroxypropyl cellulose.
  • COMPOSITIN should read COMPOSITION In Column 1, line 1, in Title, "COMPOSI'IIN” should read COWOSITION Q In Column 2, line 7, "anti-fertility” should read antifertility In (301 2 line 63, The word cotton should be in quotation marks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
US316175A 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same Expired - Lifetime US3875300A (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US316175A US3875300A (en) 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same
FR7344027A FR2210415B1 (enrdf_load_stackoverflow) 1972-12-18 1973-12-10
GB5704473A GB1446626A (en) 1972-12-18 1973-12-10 Composition for sustained release of a medicament and method of using same
BE138771A BE808519A (fr) 1972-12-18 1973-12-11 Medicament pour relachement entretenu d'un ingredient actif et methode d'utilisation de ce medicament
ZA00739502A ZA739502B (en) 1972-12-18 1973-12-14 Compositions for sustained release of a medicament and method of using same
AU63720/73A AU6372073A (en) 1972-12-18 1973-12-17 Sustained release of a medicament
IT54360/73A IT1047937B (it) 1972-12-18 1973-12-17 Composizione per la cessione graduale di un medicamento
JP48139715A JPS49133519A (enrdf_load_stackoverflow) 1972-12-18 1973-12-17
BR9861/73A BR7309861D0 (pt) 1972-12-18 1973-12-17 Veiculo inerte para prover um desprendimento prolongado de substancia ativa
IL43839A IL43839A0 (en) 1972-12-18 1973-12-17 Compositions for sustained release of a medicament
NL7317324A NL7317324A (enrdf_load_stackoverflow) 1972-12-18 1973-12-18
DE2362991A DE2362991A1 (de) 1972-12-18 1973-12-18 Arzneipraeparate zur direkten einfuehrung in koerperhoehlen
AT1060573A AT332532B (de) 1972-12-18 1973-12-18 Verfahren zur herstellung eines intravaginal anzuwendenden arzneimittels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US316175A US3875300A (en) 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same

Publications (1)

Publication Number Publication Date
US3875300A true US3875300A (en) 1975-04-01

Family

ID=23227840

Family Applications (1)

Application Number Title Priority Date Filing Date
US316175A Expired - Lifetime US3875300A (en) 1972-12-18 1972-12-18 Composition for sustained release of a medicament and method of using same

Country Status (13)

Country Link
US (1) US3875300A (enrdf_load_stackoverflow)
JP (1) JPS49133519A (enrdf_load_stackoverflow)
AT (1) AT332532B (enrdf_load_stackoverflow)
AU (1) AU6372073A (enrdf_load_stackoverflow)
BE (1) BE808519A (enrdf_load_stackoverflow)
BR (1) BR7309861D0 (enrdf_load_stackoverflow)
DE (1) DE2362991A1 (enrdf_load_stackoverflow)
FR (1) FR2210415B1 (enrdf_load_stackoverflow)
GB (1) GB1446626A (enrdf_load_stackoverflow)
IL (1) IL43839A0 (enrdf_load_stackoverflow)
IT (1) IT1047937B (enrdf_load_stackoverflow)
NL (1) NL7317324A (enrdf_load_stackoverflow)
ZA (1) ZA739502B (enrdf_load_stackoverflow)

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50105814A (enrdf_load_stackoverflow) * 1973-12-17 1975-08-20
US3946734A (en) * 1975-02-19 1976-03-30 The United States Of America As Represented By The Secretary Of State Apparatus for controlling the release of a drug
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
US4045558A (en) * 1975-10-08 1977-08-30 Merck & Co., Inc. Pilocarpine salts
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4136145A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
DE2940146A1 (de) * 1978-10-17 1980-04-30 Stolle Res & Dev Mikroteilchen zur behandlung der inneren weiblichen geschlechtsorgane und deren verwendung
EP0016051A4 (en) * 1978-06-09 1980-07-17 Donald Entpr Inc ANTI-CONCEPT / ANTIVENERIC TAMPON.
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4265875A (en) * 1976-07-23 1981-05-05 Inveresk Research International Controlled release suppositories
US4287175A (en) * 1978-06-22 1981-09-01 Merck & Co., Inc. Contact lens wetting agents
US4309997A (en) * 1978-06-09 1982-01-12 Donald Jack W Contraceptive and/or antivenereal disease tampon
US4343787A (en) * 1975-07-29 1982-08-10 Merck & Co., Inc. Shaped ophthalmic inserts for treating dry eye syndrome
US4344968A (en) * 1978-12-09 1982-08-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical vehicle
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
WO1988008296A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C A spun fibrous cosmetic and method of use
WO1988008298A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C Rapidly dissoluble medicinal dosage unit and method of manufacture
US4784857A (en) * 1986-06-03 1988-11-15 Smith And Nephew Associated Companies Plc Drug delivery device, its preparation and use
US4841968A (en) * 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
WO1990011017A1 (en) * 1989-03-20 1990-10-04 Fuisz Pharmaceutical Ltd. A moderated spun fibrous system and method of manuacture
US4997856A (en) * 1987-04-20 1991-03-05 Fuisz Pharmaceutical Ltd. Method of producing compacted dispersable systems
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5238696A (en) * 1987-04-20 1993-08-24 Fuisz Technologies Ltd. Method of preparing a frozen comestible
US5268110A (en) * 1991-05-17 1993-12-07 Fuisz Technologies Ltd. Oil removing method
US5279849A (en) * 1992-05-12 1994-01-18 Fuisz Technologies Ltd. Dispersible polydextrose, compositions containing same and method for the preparation thereof
US5286513A (en) * 1987-04-20 1994-02-15 Fuisz Technologies Ltd. Proteinaceous food product containing a melt spun oleaginous matrix
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5380529A (en) * 1990-07-10 1995-01-10 Laboratoire Lucchini S.A. Pharmaceutical, vaginal applicable preparation and a process for its preparation
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5407676A (en) * 1990-12-14 1995-04-18 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and a method of manufacture
US5427804A (en) * 1992-03-05 1995-06-27 Fuisz Technologies Ltd. Low-fat edible proteins with maltodextrins and low-saturate oils
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
US5472731A (en) * 1987-04-20 1995-12-05 Fuisz Technologies Ltd. Protein based food product
US5501858A (en) * 1992-05-12 1996-03-26 Fuisz Technologies Ltd. Rapidly dispersable compositions containing polydextrose
US5512289A (en) * 1993-07-28 1996-04-30 Johnson & Johnson Consumer Products, Inc. Spermicidal anti-viral lubricant composition and method of using same
US5516537A (en) * 1987-04-20 1996-05-14 Fuisz Technologies Ltd. Frozen comestibles
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5520859A (en) * 1993-10-07 1996-05-28 Fuisz Technologies Ltd. Method for flash flow processing having feed rate control
US5545615A (en) * 1987-09-18 1996-08-13 Zymogenetics, Inc. A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III
US5549917A (en) * 1994-07-01 1996-08-27 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5576042A (en) * 1991-10-25 1996-11-19 Fuisz Technologies Ltd. High intensity particulate polysaccharide based liquids
US5587198A (en) * 1995-05-31 1996-12-24 Fuisz Technologies Ltd. Positive hydration method of preparing confectionery and product therefrom
US5593502A (en) * 1993-10-07 1997-01-14 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5624684A (en) * 1991-05-17 1997-04-29 Fuisz Technologies Ltd. Enzyme systems
US5651987A (en) * 1991-12-17 1997-07-29 Fuisz Technologies Ltd. Ulcer prevention and treatment composition
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5728397A (en) * 1992-05-12 1998-03-17 Fuisz Technologies Ltd. Polydextrose product and process
US5843922A (en) * 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
US5851553A (en) * 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US20040131664A1 (en) * 2003-01-03 2004-07-08 Mo Y. Joseph Topical stabilized prostaglandin E compound dosage forms
US20120058166A1 (en) * 2010-07-02 2012-03-08 Glenn Jr Robert Wayne Filaments comprising a non-perfume active agent nonwoven webs and methods for making same
US20130136784A1 (en) * 2007-10-11 2013-05-30 Robert J. Staab Methods for delivery of medication using dissolvable devices
CN114397391A (zh) * 2022-01-21 2022-04-26 苏州南医大创新中心 一种精液中与无精子症有关的分子标志物蓖麻油酸及其检测方法和应用
US11434586B2 (en) 2010-07-02 2022-09-06 The Procter & Gamble Company Filaments comprising an active agent nonwoven webs and methods for making same
US11666514B2 (en) 2018-09-21 2023-06-06 The Procter & Gamble Company Fibrous structures containing polymer matrix particles with perfume ingredients
US11679066B2 (en) 2019-06-28 2023-06-20 The Procter & Gamble Company Dissolvable solid fibrous articles containing anionic surfactants
US11925698B2 (en) 2020-07-31 2024-03-12 The Procter & Gamble Company Water-soluble fibrous pouch containing prills for hair care
US11944696B2 (en) 2010-07-02 2024-04-02 The Procter & Gamble Company Detergent product and method for making same
US11944693B2 (en) 2010-07-02 2024-04-02 The Procter & Gamble Company Method for delivering an active agent
US11951194B2 (en) 2017-01-27 2024-04-09 The Procter & Gamble Company Compositions in the form of dissolvable solid structures comprising effervescent agglomerated particles
US12029799B2 (en) 2017-05-16 2024-07-09 The Procter & Gamble Company Conditioning hair care compositions in the form of dissolvable solid structures
US12403083B2 (en) 2022-08-30 2025-09-02 The Procter & Gamble Company Dissolvable solid structure comprising first and second polymeric structurants

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE431821B (sv) * 1979-01-29 1984-03-05 Perstorp Ab Lagringsstabilt, prostaglandininnehallande medicinskt preparat
JPS5634619A (en) * 1979-08-31 1981-04-06 Ono Pharmaceut Co Ltd Production of prostaglandin vaginal suppository
JPS5832816A (ja) * 1981-08-20 1983-02-25 Shin Etsu Chem Co Ltd 避妊用フイルム製剤
JPS58206512A (ja) * 1982-05-27 1983-12-01 ウイジヤヤ・チヤンドラ 女性外用避妊膜
ES2017282A6 (es) * 1989-07-28 1991-01-16 Aguilera Franco Maria Aposito para aplicaciones de substancias activas por via transcutanea con fines terapeuticos o cosmeticos.
DE102020131179A1 (de) 2020-11-25 2022-05-25 Universität Rostock Resorbierbare dreidimensionale Hohlfaserstruktur zur Verwendung in Tamponaden und/oder Wundauflagen und Verfahren zur Herstellung einer resorbierbaren dreidimensionalen Hohlfaserstruktur zur Verwendung in Tamponaden und/oder Wundauflagen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067743A (en) * 1958-11-12 1962-12-11 Alginate Ind Ltd Alginic compounds
US3108043A (en) * 1960-05-09 1963-10-22 Ortho Pharma Corp Spermicidal sheet-like material

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067743A (en) * 1958-11-12 1962-12-11 Alginate Ind Ltd Alginic compounds
US3108043A (en) * 1960-05-09 1963-10-22 Ortho Pharma Corp Spermicidal sheet-like material

Cited By (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
JPS50105814A (enrdf_load_stackoverflow) * 1973-12-17 1975-08-20
US4136145A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US3982537A (en) * 1974-12-30 1976-09-28 Louis Bucalo Dynamic implants and method for implanting the same
US3946734A (en) * 1975-02-19 1976-03-30 The United States Of America As Represented By The Secretary Of State Apparatus for controlling the release of a drug
US4343787A (en) * 1975-07-29 1982-08-10 Merck & Co., Inc. Shaped ophthalmic inserts for treating dry eye syndrome
US4045558A (en) * 1975-10-08 1977-08-30 Merck & Co., Inc. Pilocarpine salts
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4265875A (en) * 1976-07-23 1981-05-05 Inveresk Research International Controlled release suppositories
US4292300A (en) * 1976-07-23 1981-09-29 Inveresk Research International Controlled release suppositories
US4309997A (en) * 1978-06-09 1982-01-12 Donald Jack W Contraceptive and/or antivenereal disease tampon
EP0016051A4 (en) * 1978-06-09 1980-07-17 Donald Entpr Inc ANTI-CONCEPT / ANTIVENERIC TAMPON.
US4287175A (en) * 1978-06-22 1981-09-01 Merck & Co., Inc. Contact lens wetting agents
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
DE2940146A1 (de) * 1978-10-17 1980-04-30 Stolle Res & Dev Mikroteilchen zur behandlung der inneren weiblichen geschlechtsorgane und deren verwendung
US4344968A (en) * 1978-12-09 1982-08-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical vehicle
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
EP0250125A3 (en) * 1986-06-03 1989-04-19 Smith And Nephew Associated Companies P.L.C. Drug delivery device, its preparation and use
US4784857A (en) * 1986-06-03 1988-11-15 Smith And Nephew Associated Companies Plc Drug delivery device, its preparation and use
US4841968A (en) * 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
WO1988008298A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C Rapidly dissoluble medicinal dosage unit and method of manufacture
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4873085A (en) * 1987-04-20 1989-10-10 Fuisz Pharmaceutical Ltd. Spun fibrous cosmetic and method of use
US5472731A (en) * 1987-04-20 1995-12-05 Fuisz Technologies Ltd. Protein based food product
US4997856A (en) * 1987-04-20 1991-03-05 Fuisz Pharmaceutical Ltd. Method of producing compacted dispersable systems
WO1988008296A1 (en) * 1987-04-20 1988-11-03 Fuisz Richard C A spun fibrous cosmetic and method of use
US5238696A (en) * 1987-04-20 1993-08-24 Fuisz Technologies Ltd. Method of preparing a frozen comestible
US5490993A (en) * 1987-04-20 1996-02-13 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun matrix and product thereof
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
US5286513A (en) * 1987-04-20 1994-02-15 Fuisz Technologies Ltd. Proteinaceous food product containing a melt spun oleaginous matrix
US5516537A (en) * 1987-04-20 1996-05-14 Fuisz Technologies Ltd. Frozen comestibles
US5374447A (en) * 1987-04-20 1994-12-20 Fuisz Technologies Ltd. Method of preparing a reduced-fat meat product
US5503862A (en) * 1987-04-20 1996-04-02 Fuisz Technologies Ltd. Method of subjecting a protein-containing material to flash flow processing and product thereof
US5545615A (en) * 1987-09-18 1996-08-13 Zymogenetics, Inc. A method of inhibiting fertilization by alpha-1-antitrypsin or antithrombin III
WO1990011017A1 (en) * 1989-03-20 1990-10-04 Fuisz Pharmaceutical Ltd. A moderated spun fibrous system and method of manuacture
US5380529A (en) * 1990-07-10 1995-01-10 Laboratoire Lucchini S.A. Pharmaceutical, vaginal applicable preparation and a process for its preparation
US5407676A (en) * 1990-12-14 1995-04-18 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and a method of manufacture
US5268110A (en) * 1991-05-17 1993-12-07 Fuisz Technologies Ltd. Oil removing method
US6129926A (en) * 1991-05-17 2000-10-10 Fuisz Technologies Ltd. Flash flow processing of thermoplastic polymers and products made therefrom
US5624684A (en) * 1991-05-17 1997-04-29 Fuisz Technologies Ltd. Enzyme systems
US5429836A (en) * 1991-10-25 1995-07-04 Fuisz Technologies Ltd. Saccharide-based matrix
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5576042A (en) * 1991-10-25 1996-11-19 Fuisz Technologies Ltd. High intensity particulate polysaccharide based liquids
US5709876A (en) * 1991-10-25 1998-01-20 Fuisz Technologies Ltd. Saccharide-based matrix
US5597608A (en) * 1991-10-25 1997-01-28 Fuisz Technologies Ltd. Saccharide-based matrix incorporating maltodextrin and process for making
US5651987A (en) * 1991-12-17 1997-07-29 Fuisz Technologies Ltd. Ulcer prevention and treatment composition
US5427804A (en) * 1992-03-05 1995-06-27 Fuisz Technologies Ltd. Low-fat edible proteins with maltodextrins and low-saturate oils
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5279849A (en) * 1992-05-12 1994-01-18 Fuisz Technologies Ltd. Dispersible polydextrose, compositions containing same and method for the preparation thereof
US5728397A (en) * 1992-05-12 1998-03-17 Fuisz Technologies Ltd. Polydextrose product and process
US5501858A (en) * 1992-05-12 1996-03-26 Fuisz Technologies Ltd. Rapidly dispersable compositions containing polydextrose
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5512289A (en) * 1993-07-28 1996-04-30 Johnson & Johnson Consumer Products, Inc. Spermicidal anti-viral lubricant composition and method of using same
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5827563A (en) * 1993-09-10 1998-10-27 Fuisz Technologies Ltd. Spheroidal crystal sugar
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5601076A (en) * 1993-09-10 1997-02-11 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5866163A (en) * 1993-09-10 1999-02-02 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5851553A (en) * 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5520859A (en) * 1993-10-07 1996-05-28 Fuisz Technologies Ltd. Method for flash flow processing having feed rate control
US5593502A (en) * 1993-10-07 1997-01-14 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5597416A (en) * 1993-10-07 1997-01-28 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5853762A (en) * 1994-06-14 1998-12-29 Fuisz Technologies Ltd Delivery of controlled-release system(s)
US5733577A (en) * 1994-06-14 1998-03-31 Fuisz Technologies Ltd. Delivery of controlled-release system (s)
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5851552A (en) * 1994-06-14 1998-12-22 Fuisz Technologies, Ltd. Delivery of controlled-release system(s)
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5549917A (en) * 1994-07-01 1996-08-27 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5824342A (en) * 1994-07-01 1998-10-20 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5582855A (en) * 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5843922A (en) * 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5744180A (en) * 1994-08-05 1998-04-28 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5633027A (en) * 1994-08-05 1997-05-27 Fuisz Technologies Ltd. Confectioneries containing stabilized highly odorous flavor component delivery systems
US5587198A (en) * 1995-05-31 1996-12-24 Fuisz Technologies Ltd. Positive hydration method of preparing confectionery and product therefrom
US5804247A (en) * 1995-05-31 1998-09-08 Fuisz Technologies Ltd. Positive hydration method of preparing confectionary and product therefrom
US20040131664A1 (en) * 2003-01-03 2004-07-08 Mo Y. Joseph Topical stabilized prostaglandin E compound dosage forms
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20130136784A1 (en) * 2007-10-11 2013-05-30 Robert J. Staab Methods for delivery of medication using dissolvable devices
US11434586B2 (en) 2010-07-02 2022-09-06 The Procter & Gamble Company Filaments comprising an active agent nonwoven webs and methods for making same
US20120058166A1 (en) * 2010-07-02 2012-03-08 Glenn Jr Robert Wayne Filaments comprising a non-perfume active agent nonwoven webs and methods for making same
US11944696B2 (en) 2010-07-02 2024-04-02 The Procter & Gamble Company Detergent product and method for making same
US11944693B2 (en) 2010-07-02 2024-04-02 The Procter & Gamble Company Method for delivering an active agent
US11970789B2 (en) 2010-07-02 2024-04-30 The Procter & Gamble Company Filaments comprising an active agent nonwoven webs and methods for making same
US12194118B2 (en) 2010-07-02 2025-01-14 The Procter & Gamble Company Detergent product and method for making same
US11951194B2 (en) 2017-01-27 2024-04-09 The Procter & Gamble Company Compositions in the form of dissolvable solid structures comprising effervescent agglomerated particles
US12029799B2 (en) 2017-05-16 2024-07-09 The Procter & Gamble Company Conditioning hair care compositions in the form of dissolvable solid structures
US11666514B2 (en) 2018-09-21 2023-06-06 The Procter & Gamble Company Fibrous structures containing polymer matrix particles with perfume ingredients
US11679066B2 (en) 2019-06-28 2023-06-20 The Procter & Gamble Company Dissolvable solid fibrous articles containing anionic surfactants
US11925698B2 (en) 2020-07-31 2024-03-12 The Procter & Gamble Company Water-soluble fibrous pouch containing prills for hair care
CN114397391A (zh) * 2022-01-21 2022-04-26 苏州南医大创新中心 一种精液中与无精子症有关的分子标志物蓖麻油酸及其检测方法和应用
US12403083B2 (en) 2022-08-30 2025-09-02 The Procter & Gamble Company Dissolvable solid structure comprising first and second polymeric structurants

Also Published As

Publication number Publication date
IT1047937B (it) 1980-10-20
GB1446626A (en) 1976-08-18
FR2210415A1 (enrdf_load_stackoverflow) 1974-07-12
NL7317324A (enrdf_load_stackoverflow) 1974-06-20
IL43839A0 (en) 1974-03-14
DE2362991A1 (de) 1974-06-20
ATA1060573A (de) 1976-01-15
BE808519A (fr) 1974-06-11
ZA739502B (en) 1975-07-30
FR2210415B1 (enrdf_load_stackoverflow) 1977-04-15
BR7309861D0 (pt) 1974-09-24
AT332532B (de) 1976-10-11
JPS49133519A (enrdf_load_stackoverflow) 1974-12-21
AU6372073A (en) 1975-06-19

Similar Documents

Publication Publication Date Title
US3875300A (en) Composition for sustained release of a medicament and method of using same
US4317447A (en) Drug delivery system
US4069307A (en) Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3903880A (en) Intrauterine device for managing the reproductive process
US4016251A (en) Vaginal drug dispensing device
US4052505A (en) Ocular therapeutic system manufactured from copolymer
US4144317A (en) Device consisting of copolymer having acetoxy groups for delivering drugs
US4160020A (en) Therapeutic device for osmotically dosing at controlled rate
US3887699A (en) Biodegradable polymeric article for dispensing drugs
US3921636A (en) Novel drug delivery device
US3888975A (en) Erodible intrauterine device
US3918452A (en) Tampons impregnated with contraceptive compositions
US4629449A (en) Vaginal dispenser for dispensing beneficial hormone
US3863633A (en) Composition containing a substance showing a topical effect on the eye, and a method of preparing the same
US5004601A (en) Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4402695A (en) Device for delivering agent in vagina
US5139790A (en) Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4542020A (en) Long-lasting adhesive antifungal suppositories
US3916899A (en) Osmotic dispensing device with maximum and minimum sizes for the passageway
US3896819A (en) IUD having a replenishing drug reservoir
US5556633A (en) Drug delivery ophthalmic insert and method for preparing same
US4011312A (en) Prolonged release drug form for the treatment of bovine mastitis
US5244668A (en) Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4308867A (en) Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals
US3948262A (en) Novel drug delivery device